Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
We are pleased to introduce our two new HSO reports.
Tuesday, May 29th 2018, 9:00 AM to 5:30 PM
Gesellschaft der Ärzte
Frankgasse 8, 1090 Vienna
By invitation only
Philosophical Dialogue on 'Individual vs. collective benefit: Can the greatest possible benefit be calculated? Can the individual understand collective benefits?'
This Information is available in German only.
Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA report
Since several years, numerous new non-invasive prenatal tests (NIPTs) have been available to identify common chromosomal anomalies. Most NIPTs are available for trisomies 21, 18 and 13 and sex chromosome aneuploidies, but many laboratories have expanded their range of analysis to include other trisomies and common microdeletions. The main advantage of NIPT compared to the conventional screening approach is the ease of implementation and non-invasiveness of the assay, as well as the potential reduction in false-positive [FP] results. An introduction of non-invasive genetic testing has ethical, social and organizational implications that need to be considered.
Publication: LBI-HTA Project report No. 103: http://eprints.hta.lbg.ac.at/1153/
Contact: Claudia Wild
We are pleased to introduce our new HSO report.
MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EunetHTA report
MammaPrint® is a test that measures the activity of certain genes within the tumour cells to estimate the likelihood of the tumour to return and spread to other organs, where it becomes incurable. Based on the outcome of MammaPrint®, depending whether the tumour has a low or high risk of returning, and in consultation with the clinician, it can be determined whether or not additional chemotherapy is needed after surgery. This 'gene expression test' is analysing the activity of 70 genes in the breast tumour and claims to be a tumour fingerprint.
Publication: LBI-HTA Project report No.102: http://eprints.hta.lbg.ac.at/1147
Contact: Claudia Wild